Business

Codex View

Cigna is two businesses with very different economics: Evernorth moves enormous pharmacy volume at thin margins, while Cigna Healthcare turns a much smaller revenue base into a larger share of profit by pricing medical risk and admin fees correctly. The market often frames CI as just another managed-care stock, but the real question is whether Evernorth's scale economics and Cigna Healthcare's underwriting discipline can both hold during the rebate-model transition and after the Medicare Advantage exit on March 19, 2025.

How This Business Actually Works

Takeaway: Evernorth produces the volume, but Cigna Healthcare still produces more profit per dollar of revenue.

Evernorth is basically a toll road on drug spend. It wins huge employer, health plan and government contracts, adjudicates claims, manages formularies and rebates, and then routes more valuable specialty and home-delivery volume through owned assets. That is why volume matters so much: the better the claim volume and specialty mix, the more leverage Cigna has with pharmacies, manufacturers and wholesalers.

Cigna Healthcare is a different animal. About 79% of medical customers are ASO, where Cigna mostly earns fees and network access with limited claims risk, but 68% of segment revenue still comes from insured products, where pricing errors show up fast in the medical care ratio. Incremental profit comes from keeping Evernorth's affordability economics, growing specialty volume, and repricing insured and stop-loss business faster than utilization rises. Management also says Evernorth's three largest clients are renewed through the end of the decade, which helps visibility but also tells you concentration is real.

The Playing Field

Takeaway: CI sits in the industry's middle ground: more diversified than a pure insurer, but without UnitedHealth's clear margin leadership.

The best peer is still UnitedHealth, because Optum shows what this model looks like when the services platform has both scale and superior economics. Elevance is the cleaner insurance comparison. CVS proves that more vertical integration does not automatically mean better returns. Humana, Centene and Molina show the other side of the business: when government-heavy books are mispriced, membership can look fine while margins fall apart.

Cigna's real advantage is not a magical moat. It is a useful but fragile combination of PBM scale, specialty assets, and a large ASO employer base that gives it data, network relevance and cross-sell opportunities. What good looks like in this industry is simple: keep service volumes growing, avoid giving all of that value back in pricing, and do not let insured medical trend outrun premiums.

Is This Business Cyclical?

Takeaway: The cycle hits CI through medical utilization and pricing lag, not through classic demand destruction.

The cleanest example is COVID. Deferred care pushed Cigna Healthcare's medical care ratio down to 78.3% in 2020, then the snapback in testing, treatment, vaccines and deferred procedures drove it up to 84.0% in 2021. The next leg was normal rate and utilization management: 81.7% in 2022 and 81.3% in 2023. Then the pressure returned through stop-loss in 2024 and individual-market medical costs in 2025, even after the Medicare Advantage sale.

That is why this business should be read as a pricing and claims-management cycle, not an economic volume cycle. Evernorth can keep growing scripts while the insured book gets squeezed, and consolidated free cash flow can stay sturdy even when one underwriting pocket has a bad year. The analyst mistake is to watch membership first and MCR second. The order should be reversed.

The Metrics That Actually Matter

Takeaway: Four numbers explain most of the value creation: scripts, Evernorth margin, medical care ratio, and free-cash-flow margin.

Scripts come first because scale is what gets Evernorth a seat at the table with large employers, pharmacies and manufacturers. Evernorth margin comes second because volume without retained economics is not worth much. Medical care ratio is the key risk gauge because a 100 bps miss in the insured book can erase a lot of PBM progress. Free-cash-flow margin is the quality check: it tells you whether accounting growth is still turning into cash after capex and working capital. Adjusted EPS is useful, but only as the output of these drivers, not the starting point.

What I'd Tell a Young Analyst

Takeaway: Start with unit economics, not the headline multiple.

Watch Evernorth like a distributor with bargaining power, not like a software company with naturally expanding margins. If claim volume grows but Evernorth pre-tax margin keeps bleeding lower, scale is helping clients more than shareholders. Watch Cigna Healthcare like an underwriter: stop-loss severity, individual-market pricing, and medical care ratio matter more than raw membership.

The thesis gets better if the rebate-free PBM transition protects retention and holds Evernorth near its current margin band while Cigna Healthcare brings MCR back under control. The thesis gets worse if CI needs repeated catch-up pricing in stop-loss and IFP while Evernorth gives up economics to defend volume. That is the whole game.

Claude View

Know the Business

Cigna Group is a pharmacy-services company that happens to also insure people. Roughly 85% of revenue flows through Evernorth Health Services, a PBM and specialty pharmacy platform, while Cigna Healthcare provides employer medical benefits at thin margins. The market often prices CI as a health insurer, but the real economic engine is drug distribution and rebate intermediation – a high-throughput, low-margin-per-claim business where scale and contract retention determine everything. The single biggest risk the market may be underestimating is the structural margin compression from the transition to a rebate-free pharmacy model beginning in 2027-2028.

How This Business Actually Works

Cigna Group operates two economically distinct businesses under one roof.

Evernorth Health Services (~$235B in 2025 adjusted revenue, ~73% of pre-tax adjusted operating income) is the drug supply chain. Express Scripts adjudicates pharmacy claims for health plans, employers, and government programs. It earns money three ways: (1) the spread between what it pays pharmacies and what it charges plan sponsors, (2) fees for administering benefit programs, and (3) a share of rebates negotiated with drug manufacturers. Accredo, the specialty pharmacy, and CuraScript, the specialty distributor, add higher-margin volume. This business processes ~2.2 billion adjusted claims per year.

Cigna Healthcare (~$47B in 2025 adjusted revenue, ~27% of pre-tax adjusted operating income) underwrites and administers employer medical benefits. About 79% of medical customers are in self-funded ASO arrangements where CI earns administrative fees but does not bear claims risk. The remaining 21% are insured (guaranteed cost or experience-rated), where CI takes premium and pays claims.

The analogy: Evernorth is a toll road for prescription drugs – massive volume, thin per-unit economics, nearly impossible to displace once embedded in a plan sponsor's workflow. Cigna Healthcare is the adjacent insurance operation that feeds Evernorth captive volume and earns modest underwriting margins.

The critical detail: Evernorth's revenue grew 53% in two years while Cigna Healthcare's shrank 8%, largely due to the Medicare Advantage divestiture to HCSC for $4.9B in March 2025. CI is deliberately concentrating on drug distribution and services over insurance risk.

Cost structure: Pharmacy and service costs ($215B) are ~78% of total revenue and largely pass-through – drug costs flow in and out. Medical costs ($34.3B) represent the insured risk exposure. SG&A ($14.6B) is the controllable overhead at ~5.3% of revenue, declining as a ratio. The economic surplus comes from negotiating better drug prices than what clients pay, managing specialty pharmacy margins, and earning fees on a growing base of administered claims.

The Playing Field

Cigna competes in two overlapping arenas: PBM/pharmacy services (against CVS Caremark and UnitedHealth/Optum Rx) and health benefits (against UnitedHealthcare, Elevance, Humana, and Centene). The peer set reveals that CI's differentiation lies in the PBM-first model.

What the peer set reveals:

• CI has the highest ROE in the group at 15.1% despite thin net margins, because of massive leverage through its balance sheet ($31.5B in debt, $45B in goodwill from the Express Scripts acquisition). This is a capital-structure-driven return, not an operating superiority.
• Elevance (ELV) is the best pure-play health insurer – higher net margins than CI with cleaner operating economics. ELV is what Cigna Healthcare would look like as a standalone.
• CVS and Centene are struggling. CVS's Aetna acquisition has delivered sub-3% ROE. Centene posted a net loss in 2025. These are cautionary tales about integration complexity.
• UNH is the standard. It runs the largest integrated health services platform (Optum + UnitedHealthcare) and earns 2.7% net margins on $448B in revenue. CI's Evernorth is the closest structural peer to Optum, but UNH trades at nearly 2x CI's P/E, reflecting the market's trust in UNH's execution and diversification.

Is This Business Cyclical?

This business has low economic cyclicality but high regulatory and political cyclicality. Drug utilization and employer health coverage are relatively recession-resistant – people take medications regardless of GDP growth, and employer-sponsored coverage is sticky.

Key observations:

• Revenue never declined, even through COVID-19 (FY2020). The jump from FY2023 to FY2024 (+$52B) reflects Evernorth contract wins, not organic medical growth.
• Operating income has been remarkably stable at $8-9.5B, varying less than 15% peak-to-trough over seven years. This is a spread business, not a volume-sensitive manufacturer.
• Net income is volatile due to one-time items (FY2020 gains, FY2024 VillageMD impairment), not operating weakness. Adjusted EPS tells a cleaner story: $25.09 (2023) -> $27.33 (2024) -> $29.84 (2025), growing at a steady ~9% annually.
• The real cycle risk is political. PBM regulation, drug pricing reform, FTC scrutiny of rebate practices, and Medicare/Medicaid rate changes hit margins unpredictably. The 2025 Medicare Advantage divestiture was partly a response to deteriorating government program economics.

The Metrics That Actually Matter

Why these five metrics matter more than surface ratios:

1. Medical Care Ratio – the single most important number for Cigna Healthcare's insured book. It has risen 310 bps in two years. When MCR exceeds ~85%, insured margins compress toward zero. CI is managing this by shedding Medicare Advantage and focusing on employer business, but the IFP book drove deterioration in 2025.

2. Evernorth Pre-Tax Margin – declining from 4.2% to 3.1% over two years despite revenue growing 53%. This is the biggest strategic tension: CI is investing in rebate-free models, new specialty pharmacy capacity, and client onboarding, all of which compress near-term margins. If margin stabilizes at 3%+, the business works. If it drifts below 2.5%, the Express Scripts acquisition thesis weakens.

3. Adjusted EPS – strips out VillageMD write-downs, amortization of Express Scripts intangibles, and restructuring charges. This is the metric management steers toward and the one that drives buyback math. 9% annualized growth is credible.

4. Pharmacy Claim Volume – the tonnage metric. More claims = more bargaining power with pharmacies and manufacturers = better unit economics. Volume grew 40% in two years, largely from Centene and Prime onboarding.

5. Free Cash Flow – $8.4B in 2025 on a $74B market cap = ~11% FCF yield. This is the cheapness argument. Even with FCF declining from the 2023 peak, CI generates enough cash to fund $5-6B in annual buybacks and dividends while carrying $31B in debt.

The gap between FCF and dividends is deployed into share buybacks. Outstanding shares fell from ~299M (2022) to ~263M (2025), a 12% reduction in three years. This is the primary EPS growth engine alongside organic operating growth.

What I'd Tell a Young Analyst

Watch the Evernorth margin, not the headline revenue. Revenue growth in drug distribution is mechanically high because drug prices keep rising and client onboarding inflates the top line. What matters is whether CI retains its share of the spread. The rebate-free model transition (2027-2028) will temporarily depress margins – the question is whether transparency attracts enough new clients to offset it.

The Express Scripts goodwill ($45B) is the elephant. This represents 29% of total assets and exceeds total equity. CI paid $67B for Express Scripts in 2018. If PBM economics permanently deteriorate, impairment risk is real. But the business has generated $50B+ in cumulative operating cash flow since the acquisition, so the cash-on-cash return has been strong.

Ignore GAAP net income in any given year. The VillageMD impairment ($2.7B in 2024), the HCSC sale gain/loss, deferred tax charges, and amortization of Express Scripts intangibles make GAAP earnings a terrible signal. Adjusted EPS and FCF tell the truth.

The moat is real but narrowing. CI's PBM scale (2.2B claims), specialty pharmacy network (Accredo), and long-term client contracts create genuine switching costs. But Amazon Pharmacy, Mark Cuban's Cost Plus model, and state-level PBM regulation are eroding the rebate-intermediation value proposition. CI's move to rebate-free pricing is a defensive acknowledgment that the old model's days are numbered.

What would change the thesis: (1) Loss of Centene contract at renewal (currently extended through end of decade – low probability near-term but existential-level concentration risk); (2) Federal legislation that bans PBM spread pricing or mandates full rebate pass-through; (3) Sustained MCR above 87% forcing exit from insured employer business; (4) Evernorth margin falling below 2.5% indicating the scale economics no longer work.

At 8.9x forward earnings and an ~11% FCF yield, CI is priced for mediocrity. The business is better than that, but the market is right to worry about the structural transition in pharmacy services economics.